Have a feature idea you'd love to see implemented?
Let us know!
ATRA Atara Biotherapeutics Inc
Price (delayed)
$10.61
Market cap
$61.11M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$25.78
Enterprise value
$87.34M
Atara Biotherapeutics, Inc.(@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers
Highlights
The gross profit has soared by 66% from the previous quarter
The EPS has soared by 63% YoY and by 34% from the previous quarter
The equity has dropped by 78% year-on-year but it has grown by 18% since the previous quarter
Atara Biotherapeutics's quick ratio has surged by 69% QoQ but it has shrunk by 66% YoY
Key stats
What are the main financial stats of ATRA
Market
Valuations
Earnings
Shares outstanding
5.76M
Market cap
$61.11M
Enterprise value
$87.34M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.87
Revenue
$100.44M
EBIT
-$128.37M
EBITDA
-$111.16M
Free cash flow
-$94.85M
Per share
Balance sheet
Liquidity
EPS
-$25.78
Free cash flow per share
-$12.7
Book value per share
-$18.42
Revenue per share
$13.45
TBVPS
$19.11
Total assets
$142.71M
Total liabilities
$233.25M
Debt
$72.83M
Equity
-$90.54M
Working capital
-$64.12M
Debt to equity
-0.8
Current ratio
0.59
Quick ratio
0.44
Net debt/EBITDA
-0.24
Margins
Efficiency
Dividend
EBITDA margin
-110.7%
Gross margin
82.7%
Net margin
-132.6%
Operating margin
-130.6%
Return on assets
-90.2%
Return on equity
N/A
Return on invested capital
-393.8%
Return on capital employed
N/A
Return on sales
-127.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ATRA stock price
How has the Atara Biotherapeutics stock price performed over time
Intraday
-0.66%
1 week
-16.91%
1 month
14.46%
1 year
-15.99%
YTD
-17.24%
QTD
30.5%
Financial performance
How have Atara Biotherapeutics's revenue and profit performed over time
Revenue
$100.44M
Gross profit
$83.07M
Operating income
-$131.2M
Net income
-$133.16M
Gross margin
82.7%
Net margin
-132.6%
ATRA's operating margin has surged by 98% year-on-year and by 54% since the previous quarter
The net margin has soared by 98% YoY and by 54% from the previous quarter
The gross profit has soared by 66% from the previous quarter
Atara Biotherapeutics's revenue has surged by 61% QoQ
Growth
What is Atara Biotherapeutics's growth rate over time
Valuation
What is Atara Biotherapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
0.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.87
The EPS has soared by 63% YoY and by 34% from the previous quarter
The equity has dropped by 78% year-on-year but it has grown by 18% since the previous quarter
ATRA's P/S is 70% below its last 4 quarters average of 2.6
Atara Biotherapeutics's revenue has surged by 61% QoQ
Efficiency
How efficient is Atara Biotherapeutics business performance
The ROS has soared by 98% YoY and by 55% from the previous quarter
Atara Biotherapeutics's return on invested capital has decreased by 36% QoQ
The company's return on assets rose by 21% QoQ and by 13% YoY
Dividends
What is ATRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ATRA.
Financial health
How did Atara Biotherapeutics financials performed over time
The total assets is 39% less than the total liabilities
Atara Biotherapeutics's quick ratio has surged by 69% QoQ but it has shrunk by 66% YoY
Atara Biotherapeutics's current ratio has plunged by 61% YoY but it has increased by 40% from the previous quarter
The debt is 180% more than the equity
The equity has dropped by 78% year-on-year but it has grown by 18% since the previous quarter
ATRA's debt to equity has surged by 50% year-on-year but it is down by 18% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.